OS Therapies ends $18M at-the-market stock program
OS Therapies Incorporated terminated its At Market Issuance Sales Agreement with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC.
Rhea-AI Filing Summary
OS Therapies Incorporated terminated its At Market Issuance Sales Agreement with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC. The agreement, dated August 8, 2025, allowed the company to offer and sell common stock from time to time with an aggregate offering price of up to $18,000,000.
The company had sold an aggregate of 282,679 shares of common stock for aggregate gross proceeds of approximately $530,162 under the agreement and related prospectus supplement, leaving approximately $17,469,838 unsold. The termination notice was delivered on July 23, 2026 and became effective on July 28, 2026. No termination fees or other payments were due by either party, and no further shares may be offered or sold under this program.
Positive
- None.
Negative
- None.
Filing Explained
The completed sale of
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
ATM program size: $18,000,000
Shares sold under ATM: 282,679 shares
Gross proceeds from ATM: approximately $530,162
+2 more
5 metrics
ATM program size
$18,000,000
Aggregate offering price capacity under the At Market Issuance Sales Agreement
Shares sold under ATM
282,679 shares
Total common shares sold before termination of the sales agreement
Gross proceeds from ATM
approximately $530,162
Aggregate gross proceeds from shares sold under the agreement and prospectus supplement
Unsold ATM capacity
approximately $17,469,838
Remaining portion of the $18,000,000 capacity at the time of termination
Termination effective date
July 28, 2026
Date the At Market Issuance Sales Agreement termination became effective
Key Terms
At Market Issuance Sales Agreement, prospectus supplement, aggregate offering price, emerging growth company
4 terms
At Market Issuance Sales Agreement financial
"termination of the At Market Issuance Sales Agreement, dated August 8, 2025"
An at market issuance sales agreement is a setup where a company arranges for an agent to sell newly issued shares directly into the public market at the current trading price, usually over time as needed. It matters to investors because it gives the company quick, flexible access to cash without setting a fixed price, but can dilute existing shareholders and affect the stock’s supply and short‑term price behavior—like a shop owner adding extra items to a shelf and selling them at whatever the going price is.
prospectus supplement regulatory
"the Company filed a prospectus supplement relating to the Sales Agreement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
aggregate offering price financial
"offer and sell shares of its common stock having an aggregate offering price of up to $18,000,000"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What agreement did OS Therapies (OSTX) terminate on July 23, 2026?
OS Therapies Incorporated terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading. The agreement, dated August 8, 2025, allowed sales of common stock through these agents under a related prospectus supplement filed on August 25, 2025.
What was the maximum size of OS Therapies’ (OSTX) at-the-market program?
The at-the-market program permitted OS Therapies to offer and sell common stock with an aggregate offering price of up to $18,000,000. This limit was established in the At Market Issuance Sales Agreement and reflected in the company’s August 25, 2025 prospectus supplement.
What unsold capacity remained under OS Therapies’ (OSTX) at-the-market program?
At termination, approximately $17,469,838 of the original $18,000,000 aggregate offering capacity remained unsold under the At Market Issuance Sales Agreement and prospectus supplement. Following termination, no further shares may be offered or sold under this program.
When did OS Therapies’ (OSTX) sales agreement termination become effective?
OS Therapies delivered its termination notice on July 23, 2026, and the termination of the At Market Issuance Sales Agreement became effective on July 28, 2026. After that effective date, no additional shares can be sold under the agreement or related prospectus supplement.
Did OS Therapies (OSTX) incur any fees for terminating the sales agreement?
No. In connection with ending the At Market Issuance Sales Agreement, no termination fees or other payments were due by either OS Therapies or the sales agents. The agreement simply ceased to permit additional common stock offerings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
